Funding
← Back to your selection

Freeflow Ventures

Activity from announced rounds

Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$18.2M
3 disclosed · full round size, not this investor’s share

By stage

Pre-seed1
Seed1
Series A1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection
TippingPoint Biosciences

Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer

$4.5MSeed
Role not disclosed
Sift Biosciences

Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases

$3.7MPre-Seed
Role not disclosed
Vivere Oncotherapies

Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells.

$10MSeries A
Role not disclosed